Apimeds Pharmaceuticals US, Inc. (APUS) Institutional Ownership

Ownership Summary

A total of 3 institutions have reported a stake in Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) as of December 2025, according to recent 13F filings with the SEC.

• These investors collectively held 3.2% of the company's total shares outstanding in December 2025, down from 3.7% in September 2025.
• The company experienced a 7.96% quarterly change in institutional shares held, alongside an unavailable change in total owners annually.
• During the quarter, 2 institutions bought more Apimeds Pharmaceuticals US shares, 0 sold shares, and 1 of the 3 total investors held their position steady.
• Collectively, institutional investors increased their stake in Apimeds Pharmaceuticals US to 333.57K shares as of December 2025, a change that is up by 24.58K shares quarter on quarter and down N/A shares year over year.
• Hemenway Trust Co LLC's holding of 274.00K shares as of December 31, 2025 makes it the primary institutional investor in Apimeds Pharmaceuticals US, owning 2.66% of the stock.
• Among the most significant buyers of Apimeds Pharmaceuticals US during December 2025 were Hemenway Trust Co LLC (24.00K), UBS Group AG (582).
• The top 3 institutional holders of Apimeds Pharmaceuticals US for the quarter ending December 2025 included Hemenway Trust Co LLC (274.00K), VANGUARD GROUP INC (58.99K), UBS Group AG (582).